CJC-1295 DAC 2mg
Long-acting GHRH synthetic analog bound to albumin via DAC to sustain continuous GH and IGF-1 elevation in research models.
Mechanism
CJC-1295 DAC targets pituitary somatotroph GHRH receptors while using an albumin-binding DAC moiety to prolong systemic circulation and maintain continuous growth hormone release.
Dosing
Standard research protocols initiate administration at 300 mcg delivered twice weekly.
Reconstitution
Inject 2.0 mL of bacteriostatic water slowly down the vial wall to obtain a 1 mg/mL (1,000 mcg/mL) concentration.
Storage
Keep unmixed lyophilized vials at -20 °C and store the reconstituted solution refrigerated between 2 °C and 8 °C without freezing.
Mix & measure CJC-1295 DAC 2mg
Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.
Mix & measure CJC-1295 DAC 2mg
Vial strength → BAC water → target dose
Common vial sizes
Label claim
Total doses in vial: 6.7
U-100 syringe: 100 units = 1 mL
Need supplies for this protocol?
Research-grade peptides, fast shipping, competitive pricing
Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →
Track my protocol
Log each dose, build a streak, and watch your progress through this protocol's schedule.
Dosing Chart
| Phase / Day(s) | Dose & Frequency | Volume (U-100 units / mL) |
|---|---|---|
| Weeks 1–2 | 300 mcg (0.3 mg) twice weekly | 30 units (0.30 mL) |
| Weeks 3–4 | 500 mcg (0.5 mg) twice weekly | 50 units (0.50 mL) |
| Weeks 5–6 | 750 mcg (0.75 mg) twice weekly | 75 units (0.75 mL) |
| Weeks 7–12 | 1000 mcg (1 mg) twice weekly | 100 units (1.0 mL) |
Reconstitution Steps
- 1
Draw 2.0 mL of bacteriostatic water into a sterile syringe.
- 2
Release it slowly down the vial's inner wall to limit foaming.
- 3
Swirl or roll gently until fully dissolved — don't shake.
- 4
Label with the date and concentration, then refrigerate at 2–8 °C (35.6–46.4 °F), shielded from light.
Supplies Needed
Peptide Vial
2 mg CJC-1295 DAC lyophilized powder container
Insulin Syringes (U-100)
1 mL syringes for precise volume extraction and measurement
Bacteriostatic Water
Sterile diluent containing 0.9% benzyl alcohol for multi-dose reconstitution
Alcohol Swabs
Antiseptic wipes to sanitize the rubber vial stopper and injection area
Why researchers study it
GH & IGF-1 support
Fat metabolism / lipolysis
Recovery & tissue repair
Sleep & slow-wave sleep
These describe what is being studied, not proven benefits, approved uses, or promised results.
Overview
CJC-1295 DAC is an engineered synthetic secretagogue derived from growth hormone-releasing hormone (GHRH). By incorporating the Drug Affinity Complex (DAC), this molecule covalently couples with circulating endogenous albumin, extending its biological half-life significantly beyond that of unmodified native peptides. Consequently, it circumvents the rapid enzymatic degradation typically observed with short-acting somatotropic signaling molecules. In preclinical research models, CJC-1295 DAC promotes a steady, non-pulsatile elevation of growth hormone release often described in pharmacological literature as a sustained secretion or baseline plateau. This steady-state signaling cascades into downstream hepatic production of insulin-like growth factor 1 (IGF-1), permitting researchers to investigate prolonged endocrine axis activation without necessitating high-frequency administration. Investigation into CJC-1295 DAC primarily centers on endocrine signaling kinetics, cellular metabolism, tissue repair dynamics, and somatotrophic tone. Because clinical trials were historically halted, this peptide remains purely an investigational agent without regulatory approval for therapeutic or diagnostic applications in humans.
References
- 1.Teichman SL et al., J Clin Endocrinol Metab, 2006 — Prolonged stimulation of GH and IGF-1 secretion by CJC-1295, a long-acting albumin-bound GHRH analog, in healthy adults
- 2.Ionescu M, Frohman LA, J Clin Endocrinol Metab, 2006 — Pulsatile GH secretion persists during continuous CJC-1295 stimulation, but the net effect is a sustained, non-pulsatile rise in GH and IGF-1
- 3.Alba M et al., Am J Physiol Endocrinol Metab, 2006 — Once-daily CJC-1295 (a GHRH analog) normalizes growth in a GHRH-knockout mouse model — mechanistic GHRH-receptor activation
- 4.Brinkman JE et al., StatPearls (NCBI Bookshelf), 2023 — Physiology, Growth Hormone — GH/IGF-1 axis, pulsatile secretion, and downstream signalling
- 5.Ayuk J, Sheppard MC, Postgrad Med J, 2006 — Growth hormone and its disorders — physiology and risks of GH/IGF-1 excess
Supplies Needed
Suggested supplier
Research use only. Listing a supplier is not an endorsement of any protocol on this site, and nothing sold there is approved for human use.
Related protocols
View allThymosin Alpha-1 5mg
Thymosin Alpha-1 is a 28-amino-acid peptide studied for T-cell maturation, dendritic function, and immune system modulation.
View ProtocolBPC-157 + TB-500 10mg Blend
A 1:1 dual-peptide blend combining BPC-157 and TB-500 formulated to investigate complementary soft-tissue and wound-healing pathways.
View ProtocolPalmitoyl Tetrapeptide-7 200mg
A synthetic palmitoylated tetrapeptide studied in topical cosmetic formulations for modulating skin inflammation and matrix integrity.
View Protocol